Pre-existing plasma cell disorders, monoclonal gammopathy of undetermined significance or smoldering myeloma, are present in at least one-third of multiple myeloma patients. However, the proportion of patients with a pre-existing plasma cell disorder has never been determined by laboratory testing on pre-diagnostic sera. We cross-referenced our autologous stem cell transplant database with the Department of Defense Serum Repository. Serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE) and serum free light chain analysis (sFLC) were performed on all sera collected two or more years prior to diagnosis to detect a monoclonal gammopathy (M-Ig). In 30 of 90 patients, 110 pre-diagnostic samples were available from 2.2-15.3 years prior to diagnosis. A M-Ig was detected in 27 of 30 patients (90%, 95% CI 74-97%); by SPEP and/or IFE in 21 patients (77.8%), and only by sFLC in six patients (22.2%). Four patients had only one positive sample within four years prior to diagnosis, with all preceding sera negative. All four patients with light-chain/non-secretory myeloma evolved from a light-chain M-Ig. A pre-existing M-Ig is present in most MM patients prior to diagnosis. Some patients progress rapidly through a pre-malignant phase. Light-chain detected M-Ig is a new entity that requires further study.
Introduction
Multiple myeloma (MM) is a mostly incurable malignant disorder of plasma cells diagnosed in approximately 20,000 patients in the United States annually. 1 Multiple myeloma is known to evolve from pre-malignant plasma cell disorders, such as monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), in at least one-third of patients. 2 The progression to MM occurs at average rates of 1% per year for MGUS, 2 and 10% per year for SMM 3 . The risk of progression from these pre-malignant conditions to MM is affected by the level of monoclonal immunoglobulin, the presence of non-IgG gammopathy, an abnormal serum free light chain ratio, the fraction of bone marrow plasma cells bearing an aberrant phenotype, increased bone marrow plasma cells, decreased levels of polyclonal immunoglobulin, and aneuploidy. [2] [3] [4] [5] [6] [7] However, the proportion of MM that develops from a preexisting MGUS or SMM is unknown and remains an important unresolved issue in the understanding of the pathogenesis of myeloma. 8 These premalignant plasma cell disorders are asymptomatic and usually discovered during investigation for unrelated symptoms or laboratory abnormalities. 9 Therefore, it is likely that previous studies have substantially underestimated the true proportion of MM patients with a pre-existing plasma cell disorder. Epidemiologic studies support the notion that a pre-existing plasma cell disorder is nearly always present. 10 Others have suggested that a proportion of MM arises de novo without a premalignant plasma cell disorder. 11 It has also been postulated that MM that arises from a pre-existing plasma cell disorder has distinct genomic features, a unique pattern of response to therapy and a more favorable outcome. [12] [13] [14] [15] We sought to determine the proportion of patients with newly diagnosed myeloma who had a pre-existing plasma cell disorder (PPCD) -as manifested by a monoclonal gammopathyby using serum collected prior to their diagnosis. We retrieved samples from the Department of For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Defense Serum Repository, which contains the unused sera from the mandatory, periodic blood tests performed on active duty U.S. military servicemembers.
Materials and Methods
A database of patients who underwent high dose chemotherapy and autologous stem cell transplantation for MM at Walter Reed Army Medical Center was cross referenced with the Department of Defense Serum Repository (DoDSR) by the Armed Forces Health Surveillance Agency. The DoDSR prospectively collects the unused sera from periodic mandatory blood tests performed on active duty U.S. military servicemembers for medical surveillance purposes.
The repository contains 27 million samples on over 7 million individuals who have served since 1990. 16 We intentionally chose a transplant population as these younger than average myeloma patients would have been most likely to have been serving on active duty after 1990
when the repository began. All available sera collected two or more years prior to the diagnosis of MM were retrieved. Serum samples less than two years prior to diagnosis were not tested as these patients were likely to have undetected multiple myeloma. Serum protein electrophoresis (SPEP) was performed using agarose gels and inspected by a technician and one of the investigators (J.A.) (Helena Laboratories, Beaumont, TX A PPCD was detected in 27 of 30 patients (90%, 95% CI 74-97%); by SPEP and/or IFE in 21 patients (78%), and sFLC in 6 patients (22%). The PPCD was initially detected by sFLC alone in 6/27 (22.2%), IFE alone in 1/27 (7.4%), SPEP+IFE in 5/27 (18.5%), IFE+sFLC in 1/27 (3.7%), and by all three assays in 14/27 (51.2%). The Mayo Clinic Risk stratification for MGUS was determined for all evaluable patients at their initial (n=18) and immediate pre-diagnostic (n=20) samples. At initial detection of a PPCD, 7 (39%) were low risk, 9 (50%) were low- For a third patient (panel C), there was a gradual increase in both M-Ig and the sFLC ratio for several years and then a more substantial increase, particularly for the sFLC ratio, that occurred 2.5 years before the diagnosis of MM. Finally, panel G illustrates a patient with light-chain MM, in whom the sFLC ratio and free kappa light chain increased substantially three to four years prior to the diagnosis of MM. Altogether, there appeared to be a substantial increase in the sFLC ratio two or more years prior to the diagnosis of MM in seven of 10 evaluable patients (Fig. 3) .
Discussion
In this study using sera available prior to the diagnosis of multiple myeloma, we demonstrated that at least 27 of 30 (90%) of patients with MM evolve from a PPCD. We suspect that the proportion of patients with a PPCD may have been higher than 90%, as the characteristics of the negative cases may have reduced our ability to detect a PPCD. One case of IgG-myeloma had only one pre-diagnostic serum sample available at 9.5 years prior to diagnosis. The remaining two negative cases were IgD-myeloma with sera available only three and five years prior to the diagnosis. This rare isotype is characterized by the secretion of very low levels of monoclonal immunoglobulins. 17 It is clear from this study that a fraction of patients progress rapidly through a premalignant phase to MM. This is consistent with recent studies stratifying MGUS patients into groups with differing rates of annual progression, from 0.25% to 11.2%, based on several factors: an abnormal serum free light chain assay, non-IgG gammopathy, the level of bone marrow plasmacytosis, and the immunophenotypic features of bone marrow plasma cells. 5, 7 However, it is notable that in our study there were no patients who satisfied the criteria for highrisk MGUS by the Mayo Clinic model. In fact, two of the four rapidly progressing patients were low or low-intermediate risk by the Mayo Clinic risk stratification model. Unfortunately, there are no published data on progression rates for light chain MGUS.
A new entity called light-chain MGUS, defined as an abnormal serum free light chain ratio without detectable immunoglobulin heavy chain, has been described by the Mayo Clinic in a population-based prevalence study performed in Olmsted County, Minnesota. 20 The investigators reported a prevalence of about 2% in those over the age of 50. This is close to the prevalence of intact immunoglobulin MGUS, and thus more information on the natural history of this condition is needed. Our study is the first detailed report of the natural history of this entity.
Of six patients, four patients progressed to light chain/non-secretory myeloma, and the remaining to intact immunoglobulin myeloma. For light chain only or non-secretory myeloma, it has been unclear to what extent this occurs de novo, is preceded by MGUS expressing an intact immunoglobulin, or is preceded by MGUS that expresses only a light chain. Therefore, it is significant that all four cases of light-chain/non-secretory myeloma in our study were preceded by light chain MGUS.
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In seven of ten evaluable patients, there appeared to be a several fold increase in the involved free light chain ratio, either with or without a corresponding change in the intact immunoglobulin level, a few years prior to the onset of multiple myeloma (Fig. 3) . This discordance of light-chain to heavy-chain production may be a harbinger of myeloma in MGUS or SMM patients and would be consistent with prior studies showing that an increasingly abnormal serum free light ratio increases the risk of progression. 5 This finding needs confirmation in larger studies that include MGUS patients who do not progress to MM.
Our study includes a unique group of patients. As we analyzed a military population from a serum repository that began in 1990, our study population is distinctly different from other studies of MGUS and MM. First, the median age of our patients was about 20 years younger than the median age of 70 years in general MM population, which allowed us to examine the relationship of MM and MGUS in younger patients. 21 Second, nearly 50% of our patients were African-Americans, a population that is under-represented in most studies on MGUS and MM despite a more than twofold increase of both of these conditions in this group. 22 Although it is clear that a larger population of patients needs to be analyzed, our present results show no obvious differences based on age or race for either the frequency of MM without a preceding monoclonal gammopathy or for rapid progression from MGUS to MM.
In conclusion, myeloma is nearly always preceded by a pre-malignant plasma cell disorder, most commonly MGUS. MGUS affects at least 3% of adults over the age of 50. 23 The current approach to MGUS is for annual clinical follow-up with serum and urine protein electrophoresis, complete blood counts, serum creatinine and calcium concentrations. 9 It has been suggested that patients at very low risk for progression based on monoclonal immunoglobulin levels below 1.5 gm/dL, with or without an abnormal serum free light chain 
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